{"id":32120,"date":"2014-09-25T10:49:02","date_gmt":"2014-09-25T14:49:02","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32120"},"modified":"2014-09-25T10:49:02","modified_gmt":"2014-09-25T14:49:02","slug":"valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120","title":{"rendered":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/25\/2014 (wallstreetpr) \u2013\u00a0<strong>Valeant Pharmaceuticals Intl Inc (NYSE:VRX) <\/strong>yesterday said that its revenue for Q3, 2014 will be stronger than anticipated. The company pushed Allegan harder to accept its offer on this pretext.<\/p>\n<p style=\"text-align: justify;\"><strong>Better-Than-Expected Results<\/strong><\/p>\n<p style=\"text-align: justify;\">Formerly known as Biovail Corporation, Valeant, said it expects the following quarter\u2019s revenue figures to be higher than those expected by the Consensus. As highlighted in an <a href=\"http:\/\/www.marketwatch.com\/story\/valeant-offers-olive-branch-to-allergan-2014-09-24?siteid=yhoof2\" target=\"_blank\">article<\/a>, the company also mentioned that it will announce the quarter\u2019s earnings on October 20, 2014. With the announcement, Valeant further increased pressure on <strong>Allergan, Inc. (NYSE:AGN)<\/strong> for accepting its offer.<\/p>\n<p style=\"text-align: justify;\">Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been fighting to buy Allergan for the last five months and has already made proposals in conjunction with activist investor William Ackman. However, Allergan has been adamant in this context, rejecting the buy-out proposal over and over again. Hedge Fund, Pershing Square Capital Management LP, owner Mr. Ackman, has been struggling to get his offer accepted in what has become the most controversial take-over battle.<\/p>\n<p style=\"text-align: justify;\"><strong>\u201cOlive Branch\u201d Offer<\/strong><\/p>\n<p style=\"text-align: justify;\">Valeant Pharmaceuticals Intl Inc (NYSE:VRX)\u2019s latest offer came after the company announced that its earnings, excluding restructuring costs, will be better than estimates. The pharmaceutical company, which has been urging Allergan to consider its acquisition offer since April, has raised its offer to value the Botox-manufacturer at around $53 million. Valeant\u2019s latest bid is seen as a counter to Allergan\u2019s reasons for rejecting the previous offers. Allergan believes that the result of a merger would be weak organic growth. In addition, Allergan has also criticized Valeant\u2019s business strategy.<\/p>\n<p style=\"text-align: justify;\">Valeant Pharmaceuticals Intl Inc (NYSE:VRX) had publicly showcased its recent talks with Allergan in three letters. This week, Valeant\u2019s Chief Executive Officer, J. Michael Pearson had sent a letter to Allergan\u2019s CEO, David Pyott. In the letter, Pearson had willingly offered Allergan its \u201colive branch\u201d to negotiate the acquisition at the next level. In the letter dated Sept 22, 2014, he even urged Pyott to discuss the deal so as to evade a three-month proxy contest.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/25\/2014 (wallstreetpr) \u2013\u00a0Valeant Pharmaceuticals Intl Inc (NYSE:VRX) yesterday said that its revenue for Q3, 2014 will be stronger than anticipated. The company pushed [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":24793,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[6035,9716,6036,2046,2045,9574],"stock_ticker":[],"class_list":["post-32120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-allergan-inc-nyseagn","tag-j-michael-pearson","tag-nyseagn","tag-nysevrx","tag-valeant-pharmaceuticals-intl-inc-nysevrx","tag-william-ackman","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/25\/2014 (wallstreetpr) \u2013\u00a0Valeant Pharmaceuticals Intl Inc (NYSE:VRX) yesterday said that its revenue for Q3, 2014 will be stronger than anticipated. The company pushed [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-25T14:49:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)\",\"datePublished\":\"2014-09-25T14:49:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120\"},\"wordCount\":354,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\",\"keywords\":[\"Allergan Inc. (NYSE:AGN)\",\"J. Michael Pearson\",\"NYSE:AGN\",\"NYSE:VRX\",\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX)\",\"William Ackman\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120\",\"name\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\",\"datePublished\":\"2014-09-25T14:49:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120","og_locale":"en_US","og_type":"article","og_title":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)  - Wall Street PR","og_description":"Boston, MA 09\/25\/2014 (wallstreetpr) \u2013\u00a0Valeant Pharmaceuticals Intl Inc (NYSE:VRX) yesterday said that its revenue for Q3, 2014 will be stronger than anticipated. The company pushed [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-25T14:49:02+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)","datePublished":"2014-09-25T14:49:02+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120"},"wordCount":354,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","keywords":["Allergan Inc. (NYSE:AGN)","J. Michael Pearson","NYSE:AGN","NYSE:VRX","Valeant Pharmaceuticals Intl Inc (NYSE:VRX)","William Ackman"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120","url":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120","name":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","datePublished":"2014-09-25T14:49:02+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-strengthens-itself-in-battle-to-acquire-allergan-inc-nyseagn-32120#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Strengthens Itself In Battle To Acquire Allergan, Inc. (NYSE:AGN)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32120"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32120\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/24793"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32120"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}